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Respiratory infections drive hepcidin-mediated 
blockade of iron absorption leading to iron deficiency 
anemia in African children
Andrew M. Prentice1*, Amat Bah1, Momodou W. Jallow1, Amadou T. Jallow1, Saikou Sanyang1, 
Ebrima A. Sise1, Kabiru Ceesay1, Ebrima Danso1, Andrew E. Armitage2, Sant-Rayn Pasricha3, 
Hal Drakesmith2, Miriam Wathuo1, Noah Kessler1,4, Carla Cerami1, Rita Wegmüller1,5,6
Iron deficiency anemia (IDA) is the most prevalent nutritional condition worldwide. We studied the contribution 
of hepcidin-mediated iron blockade to IDA in African children. We measured hepcidin and hemoglobin weekly, 
and hematological, inflammatory, and iron biomarkers at baseline, 7 weeks, and 12 weeks in 407 anemic 
(hemoglobin < 11 g/dl), otherwise healthy Gambian children (6 to 27 months). Each child maintained remarkably 
constant hepcidin levels (P < 0.0001 for between-child variance), with half consistently maintaining levels that 
indicate physiological blockade of iron absorption. Hepcidin was strongly predicted by nurse-ascribed adverse 
events with dominant signals from respiratory infections and fevers (all P < 0.0001). Diarrhea and fecal calprotectin 
were not associated with hepcidin. In multivariate analysis, C-reactive protein was the dominant predictor of 
hepcidin and contributed to iron blockade even at very low levels. We conclude that even low-grade inflammation, 
especially associated with respiratory infections, contributes to IDA in African children.
INTRODUCTION
Iron deficiency (ID) and iron deficiency anemia (IDA) are highly 
prevalent in low-income countries (1). The 2017 Global Burden of 
Disease exercise estimated that 1.224 billion people suffer from IDA 
(2). In most of sub-Saharan Africa and many South Asian countries, 
it is the leading cause of years lived with disability and, by this mea-
sure, outweighs all other nutritional deficiencies, hemoglobinopa-
thies, and hemolytic anemias put together (2). The etiology of ID 
and IDA has hitherto been ascribed to poor diets lacking in animal 
products and containing dietary phytates and related anti-nutrients 
and to infections (especially helminths and malaria). Rigorously 
implemented efficacy trials with iron supplementation accompanied 
by multiple micronutrients achieve some resolution of ID and anemia, 
but the meta-analyzed results show a benefit of only 3 to 5 g/liter 
increase in hemoglobin (Hb) (3–6).
Hepcidin is the master regulator of iron metabolism, and its 
discovery offers fresh insights into the pathophysiology of ID and 
its consequent anemia. Hepcidin has evolved to regulate duodenal 
iron absorption and tissue iron distribution in response to competing 
signals relating to iron status and infection/inflammation (7, 8). 
Hepcidin suppression, driven by ID or a high erythropoietic drive, 
facilitates iron absorption and distribution. Hepcidin expression, 
driven by iron sufficiency/overload, infection, or inflammation, blocks 
iron absorption and sequesters iron in macrophages (7, 8). Hepcidin 
up-regulation in the acute-phase response drives the plasma hypo-
ferremia that restricts iron availability to potentially pathogenic 
microorganisms (9).
Previous studies in African children have shown that hepcidin 
levels are variably influenced by the combined effects of malaria, 
iron status, and inflammation (10, 11) and can reliably identify IDA 
and distinguish it from the anemia of infection (12). The objective 
of the current study was to examine the frequency and duration of 
elevated hepcidin to levels that would inhibit iron absorption and to 
describe the associations between elevated hepcidin, inflammation, 
infections, and iron status. To achieve this aim, we analyzed weekly 
plasma hepcidin levels over 12 weeks in a large cohort of young 
Gambian children aged 6 to 23 months participating in a randomized 
controlled trial (13).
RESULTS
Children maintain consistent levels of hepcidin
The availability of serial measurements allowed us to examine the 
variability of plasma hepcidin levels across the 12 weeks of study. 
Table 1 summarizes the baseline characteristics. The 407 participating 
subjects were selected as being anemic at recruitment (Hb < 11 g/dl) 
and made up 75% of the potentially eligible children. The proportion 
iron deficient at baseline was 58.5% [defined at ferritin <15 g/liter 
if C-reactive protein (CRP) <5 mg/liter or ferritin <30 g/liter if 
CRP >5 mg/liter]. Estimates based on raised soluble transferrin recep-
tor (sTfR) (45.7%) or low hepcidin (49.1%) were similar, given the 
uncertainties of how best to define ID in young children. Using the 
lower limit of normal for mean corpuscular volume (MCV) in African 
Americans of 63 fl, 52.6% had IDA. Hepcidin increased gradually in 
response to the universal iron supplementation in group 1 (by 
0.058 ng/ml per day; P < 0.0001) but not in the two screen-and-treat 
groups. To account for this serial increase, we incorporated “visit day” 
into all analyses. Figure 1A shows the mean ± SE of log hepcidin for 
each child displayed in rank order for all 388 children who had six or 
more hepcidin measurements. It displays a remarkable constancy of 
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hepcidin with a highly significant F ratio for the between-child vari-
ability versus within-child variability (F = 8.2, df = 386, P < 0.0001). 
Twelve-week mean hepcidin levels ranged from 0.18 to >40 ng/ml. 
Note that the smaller SEs among the children with the highest hepci-
din levels are caused by allocating the value of 50 ng/ml whenever 
enzyme-linked immunosorbent assay (ELISA) readings were beyond 
the calibration curve, and there was insufficient sample to dilute and 
repeat the analysis. Their true mean values and associated variance 
would have been higher. Fifty-two percent of the children (those in-
dicated in red in Fig. 1A) consistently maintained hepcidin levels 
above the threshold of 5.5 ng/ml, which predicts that they were 
blocking iron absorption for the greater part of the 12 weeks studied.
Table 1. Baseline characteristics of subjects. N = 407 (209 girls,  
198 boys). WBC, white blood cells. 
Mean 5th and 95th percentiles
Age at enrolment 
(months) 15.4 7.7, 22.2
Length-for-age  
(z score) −1.00 −2.45, 0.51
Weight-for-age  
(z score) −1.19 −2.67, 0.39
Weight-for-height  
(z score) −0.90 −2.36, 0.54
Hepcidin (ng/ml)* 3.09 0.05, 39.05
Hb (g/dl) 9.78 7.30, 11.90
Hematocrit (%) 27.9 21.8, 34.1
MCV (fl) 62.8 50.2, 74.1
MCHC (g/dl) 35.1 32.7, 37.3
WBC (×109 per liter) 11.9 6.2, 19.7
Granulocytes (×109  
per liter) 4.53
2.1, 8.0
Lymphocytes (×109  
per liter) 6.32 3.17, 10.53
Ferritin (g/liter)* 8.18 0.1, 62.2
UIBC (M) 64.5 40.9, 92.8
TSAT (%) 7.87 0.80, 20.9
sTfR (mg/liter) 8.92 4.73, 15.06
Serum iron (M) 5.70 0.7, 13.4
CRP (mg/liter)* 2.30 0.1, 24.5
AGP (g/liter)* 1.18 0.64, 2.23
ID
 Ferritin <15 g/liter† 50.9%
 Ferritin <15 g/liter 
if CRP <5 mg/liter or 
ferritin <30 g/liter if 
CRP >5 mg/liter
58.5%
 sTfR >8.3 mg/liter 45.7%
 Hepcidin <5.5 ng/ml 49.1%
IDA
 MCV <63 fl‡ 52.6
 MCV <71 fl§ 87.0
*Geometric means.   †Defined as ferritin <15 g/liter.   ‡Defined as 
MCV <63 fl (lower limit for African Americans).   §Defined as MCV <71 fl 
(lower limit for Caucasian Americans).
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Fig. 1. Gambian children maintain highly characteristic hepcidin levels over 
12 weeks of study. (A) Twelve-week geometric mean hepcidin values (±SE) for 
individual children put in rank order from lowest to highest. Individual means and 
the smoothed curve for all children are shown in black. Data illustrated are for all 
388 children with more than six serial measurements. Green indicates habitual iron 
absorbers (hepcidin <5.5 ng/ml); red indicates habitual iron blockers (hepcidin 
>5.5 ng/ml). (B) Data from (A) are recategorized according to quintiles of UIBC. UIBC 
concentrations: Q1, 33.7 to 52.4 M; Q2, 52.4 to 59.3 M; Q3, 59.3 to 66.8 M; Q4, 
66.8 to 74.3 M; Q5, 74.3 to 120 M. Green indicates habitual iron absorbers (hepcidin 
<5.5 ng/ml); red indicates habitual iron blockers (hepcidin >5.5 ng/ml). The propor-
tion of iron absorbers in each quintile is indicated in the inset panel and was as 
follows: Q1, 15.6%; Q2, 35.5%; Q3, 40.8%; Q4, 69.7%; Q5, 76.0%. (C) Data from (A) 
are recategorized according to clinical categories of CRP (mg/liter). Green indicates 
habitual iron absorbers (hepcidin <5.5 ng/ml); red indicates habitual iron blockers 
(hepcidin >5.5 ng/ml). The proportion of iron absorbers in each group is indicated 
in the inset panel: CRP <1, 63.3%; CRP 1 to 3, 53.6%; CRP 3 to 5, 52.2%; CRP 5 to 10, 
26.5%; CRP >10, 29.2%.
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Influence of iron status on hepcidin
Univariate analysis of factors predicting hepcidin revealed the associ-
ations listed in Table 2. None of a child’s sex, age, or anthropometry 
were associated with their hepcidin level, nor were Hb or hematocrit. 
Long-acting measures of positive iron status [ferritin, low unsatu-
rated iron binding capacity (UIBC), low transferrin, low sTfR, high 
MCV, and mean corpuscular hemoglobin (MCH)] were all strongly 
inversely associated with hepcidin (P < 0.0001). Serum iron and trans-
ferrin saturation (TSAT), which respond rapidly to recent iron in-
take, were not associated with hepcidin. Surprisingly, whether the 
children received iron supplements over the previous week also was 
not associated with hepcidin. Ferritin is both a marker of iron status 
and inflammation, and therefore, it is not an optimal marker of iron 
status. In this dataset, UIBC, which incorporates information from 
raised transferrin (an indicator of physiological effort to acquire more 
iron) and low serum iron, was the best iron status predictor of hepci-
din (note that sTfR was also a good predictor of hepcidin, but UIBC 
outperformed sTfR in the multivariate analysis described below).
Figure 1B illustrates children’s characteristic mean hepcidin values 
for each quintile of UIBC. As expected, the mean plasma hepcidin 
decreased across the quintiles and the proportion of iron absorbers 
increased from 16 to 76% (see inset panel).
Influence of inflammation on hepcidin
The markers of inflammation [CRP and 1-acid glycoprotein (AGP)], 
granulocyte number, and the granulocyte-to-lymphocyte ratio were 
strongly positively associated with hepcidin in univariate analysis 
(all P < 0.0001) (Table 2). Ferritin was also strongly positively asso-
ciated but is a confounded index of both inflammation and iron 
status. Total white cells and lymphocytes were weaker but significant 
positive correlates. Notably, fecal calprotectin was not associated 
with plasma hepcidin.
Figure 1C shows that, after allocating children to the five clini-
cally recognized CRP strata, there remained a very substantial inter-
individual difference across the subgroups. Mean plasma hepcidin 
increased with increasing CRP, and the proportion of iron absorbers 
decreased from 63 to 29% (see inset panel). CRP remained signifi-
cantly associated with plasma hepcidin levels even among children 
with CRP <1 mg/liter, which is usually considered to indicate an 
absence of inflammation (Table 2). Even in the 200 children (52% of 
sample) who had mean CRP less than 3 mg/liter, indicating low levels 
of inflammation, 42% had a mean hepcidin above the threshold 
associated with iron blockade.
Influence of infections
Maternal report of recent infection was associated with raised 
hepcidin but did not alter the proportion of iron absorbers versus 
nonabsorbers (Table 3). There were 425 registered adverse events 
(AEs), of which the subcategories fever, diarrhea, respiratory infec-
tions, and skin infections had sufficient events to warrant categorical 
analysis. Total AEs, fevers, and respiratory infections were strongly 
positively associated with hepcidin (all P < 0.0001); diarrhea and 
skin infections showed no detectable association.
Combined influences of iron status and inflammation  
on hepcidin
Multivariate analysis including all variables associated with hepcidin 
that were significant in combination (UIBC, ferritin, CRP, and 
granulocytes) explained 26.6% of the variance in hepcidin. Figure 2 
illustrates that the multivariable adjustment attenuated the range in 
mean hepcidin levels between children but, while highly attenuated, 
the between-child differences remained significant, though weakly 
so (F ratio = 1.8, df = 386, P < 0.001). Following this statistical elimi-
nation of the effect of inflammation (by use of the “estimated cell 
means” function in DataDesk, which predicts what the value would 
be in the absence of inflammation), all children had a mean hepcidin 
level below the threshold (5.5 ng/ml) and would hence be predicted 
to be good iron absorbers.
DISCUSSION
Hepcidin, the master regulator of systemic iron metabolism, has 
evolved to exert exquisite control of iron intake and its distribution 
through various body compartments in response to the competing 
and opposing signals, indicating the body’s need for iron versus the 
threat of infection (7, 8). In this study, the availability of weekly hepci-
din measurements collected as part of a randomized trial (13) reveals 
several important new insights into the regulation of hepcidin and 
its role in mediating ID in rural African children. Although living 
conditions and infection profiles vary widely across poorer areas of 
low-income countries, our demonstration that respiratory infections 
seem to play a key etiological role in IDA could have important and 
widespread implications for community prevention programs.
We show that the children maintained remarkably consistent 
levels of hepcidin across the 12 weeks of study. Hepcidin has a half-
life of <24 hours in adult humans (8) (likely shorter in young 
children) and is viewed as a relatively labile hormone with evidence 
for diurnal variation (14) and a modestly acute response to iron 
ingestion (15). The long-term stability of plasma levels in these 
children is therefore surprising, as is the very wide range, with some 
children maintaining exceptionally high hepcidin levels (>40 ng/ml 
averaged over 12 weeks). At the other extreme, there was a group of 
children maintaining hepcidin levels below our limit of detection, 
thus indicating complete hepcidin suppression.
Using stable isotope incorporation studies, we have previously 
determined that a hepcidin threshold (measured on the same ELISA) 
of 5.5 ng/ml effectively distinguishes iron absorbers from nonab-
sorbers (12, 16). Over half of the children in this study maintained 
their mean 12-week hepcidin above this threshold and hence were 
physiologically inhibiting iron absorption despite the fact that all 
subjects were anemic at screening (Hb < 11 g/dl) and that, in spite 
of the iron supplementation, 61% of all ferritin levels throughout the 
study were below the accepted cutoffs, indicating ID in children (<15 g/
liter if CRP <5 mg/liter or <30 g/liter if CRP >5 mg/liter) (17).
As anticipated, on the basis of the known physiology of hepcidin 
regulation and on previous studies, including in African children 
(10, 11, 18), hepcidin levels were strongly associated with measures of 
iron status. Somewhat surprisingly, it was the indices of longer- term 
iron status (ferritin, UIBC, sTfR, MCV, and MCH) that were good 
predictors and there was no discernible association with short- term 
indices (serum iron and TSAT) or with whether the children had re-
ceived daily iron supplements for the preceding 7 days. In common 
with previous studies (11, 18), Hb and MCH concentration (MCHC) 
were not associated with hepcidin levels. These results largely match 
previous data from a cross-sectional study of 6-month-old Kenyan 
infants by Jaeggi et al. (10), although they found a marginal associa-
tion with Hb. Neither Jaeggi nor our study assessed liver iron levels, 
Hif-derived signals, or erythroferrone (19), all of which are additional 
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regulators of hepcidin (8, 20). Inclusion of these variables would likely 
have increased the proportion of total variance we could explain, and 
they remain unexplored components of hepcidin- mediated regulation 
of iron status in such populations. It is also likely that there are some 
genetic variants (e.g., in HFE, ferroportin, TMPRSS6, or others) that 
may contribute to the intersubject variance. The relatively normal 
distribution of log hepcidin makes it unlikely that there are strong 
effects of any monogenic variants; polygenic effects are more likely.
The fact that inflammation was strongly associated with raised 
hepcidin levels is also in line with the known influences on hepcidin 
expression. What is surprising is that CRP was the strongest correlate 
of hepcidin in these young children and was significantly associated 
Table 2. Factors associated with children’s characteristic hepcidin levels. The multivariate analysis includes all the variables with a significant influence 
based on forward selection with P < 0.05. Prior iron, iron supplementation over the previous 7 days; NS, not significant.
Predictor Positive/negative association F ratio* P R
2
Univariate analysis
 Iron indices
  Log ferritin (also affected  
 by inflammation) Positive 37.0 <0.0001 17.1
  Transferrin Negative 15.2 <0.0001 13.4
  UIBC Negative 19.9 <0.0001 13.2
  sTfR Negative 22.0 <0.0001 13.0
  Serum iron – 4.4 0.04 –
  TSAT – 0.0 NS –
  Prior iron – 0.1 NS –
  Hb – 1.3 NS –
  MCV Positive 15.2 <0.0001 8.1
  MCH Positive 21.0 <0.0001 11.4
 Inflammatory markers
  Log CRP Positive 111.5 <0.0001 14.2
  Log AAGP Positive 45.4 <0.0001 6.5
  Total WBC Positive 5.3 <0.02 1.7
  Granulocytes Positive 39.1 <0.0001 3.9
  Lymphocytes Positive 6.0 0.014 1.7
  Granulocyte-to- 
 lymphocyte ratio Positive 48.2 <0.0001
 Fecal inflammatory marker
  Log calprotectin – 0.03 NS –
Multivariate analysis
 Log ferritin Positive 10.0 0.0015
26.6
 UIBC† Negative 11.3 0.0013
 Log CRP Positive 46.6 <0.0001
 Granulocyte-to-lymphocyte ratio Positive 14.9 <0.0001
 Stratified analysis of CRP as predictor of hepcidin‡
 CRP range
  All (n = 370) Positive 111.5 <0.0001 14.2
  <10 (n = 322) Positive 65.2 <0.0001 10.9
  <5 (n = 258) Positive 35.6 <0.0001 8.9
  <3 (n = 189) Positive 23.9 <0.0001 7.2
  <1 (n = 60) Positive 14.4 0.0002 3.6
 
*Adjusting for individual subject (discrete variable) and week (continuous variable). The F ratios and P values shown are from the same multivariate model, 
including the four variables shown as well as subject and week.   †UIBC and sTfR were mutually replaceable in the multivariate analysis.   ‡Log hepcidin 
against log CRP with adjustment for individual subject (discrete variable) and study week (continuous variable).
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even in the lowest category of CRP (<1 mg/liter), which is custom-
arily assumed to indicate a lack of inflammation. Defining the 
source of this inflammation has major implications for the design of 
public health interventions to combat IDA. Surprisingly, we found 
only a weak association between maternal reports of sickness in their 
children and plasma hepcidin. The children in this study were free 
of infection at baseline (by protocol) and were mostly well for the 
duration of their follow-up; mothers reported illness on 17% of oc-
casions asked, but the health conditions were generally mild child-
hood afflictions. There was almost no malaria. The more serious AEs 
provided a clearer picture. The existence of an AE was strongly 
associated with high hepcidin, as were the AE categories respiratory 
infections and fever [the latter not surprisingly as this correlates 
with elevated interleukin-6 (IL6), which is a key up-regulator of 
hepcidin (8)]. Diarrhea and skin infections were not associated 
with raised hepcidin. Our data additionally indicate that the very 
high hepcidins in some children cannot be ascribed to any clinical 
infections per se.
The strong association between hepcidin and granulocyte counts is 
noteworthy. When expressed as the granulocyte-to-lymphocyte ratio, 
granulocytes were very strongly positively associated with hepcidin. 
Environmental enteric dysfunction (EED), characterized by chronic 
damage and inflammatory infiltrate into the gut mucosa, is wide-
spread in low-income settings and is assumed to be a major driver 
of growth failure (20). Reducing EED is a key intermediary goal of 
ongoing and recently completed WASH interventions (21, 22). On 
the basis of the lactulose/mannitol permeability and similar sugar 
permeability tests, we have previously shown that EED is almost 
universal in rural Gambian children [e.g., (23)]. Given its almost 
universal prevalence, it would be surprising if EED yielded the very 
wide range of inflammation and hepcidin levels we report here; ad-
ditionally, we found that neither fecal calprotectin nor diarrhea was 
associated with elevated hepcidin. This result replicates the findings 
of Jaeggi et al. (10) who, as in this study, found that systemic inflam-
mation was very strongly associated with hepcidin, but found no 
association of hepcidin with fecal calprotectin or the gut-associated 
cytokines IL-12 and IL-17. The strong association with respiratory 
infections therefore stands out as the key finding.
The public health challenge of anemia is vividly illustrated in Fig. 3 
using data from our Keneba Biobank. The mean Hb level in children 
aged 1 to 2 years is 1 g/dl lower than the 5th centile for African- 
American children living in the United States (24), and 91% are classi-
fied as anemic according to the World Health Organization (WHO) 
definition. The green bars represent the WHO meta- analyzed average 
response to iron-plus-multiple-micronutrient interventions con-
ducted under the optimized conditions of randomized controlled trials 
(3, 4). Applying this benefit would still leave the rural Gambian chil-
dren well below the African-American 5th centile, and an estimated 
67% would still be anemic. Against this background, our current data 
may have important policy implications. The results suggest that the 
focus on nutrition-specific interventions (dietary iron sources and 
anti-nutrients) and specific infections (helminths and malaria) must 
be complemented by other approaches (25, 26), and they highlight 
the critical importance of low-grade inflammation. In actuality, half 
of the children in our study were physiologically blocking iron ab-
sorption by a finely evolved hepcidin-dependent mechanism that 
Table 3. Multivariate analysis of maternal reports of infection and physician-notified AEs as a predictor of plasma hepcidin.  
No. of events
Geometric mean hepcidin
(% >5.5 ng/ml)
F ratio P*
Illness
Yes
Illness
No
Maternal reports†
 Any sickness 341 5.43 (45%) 4.33 (45%) 8 0.0052
Clinical records‡
 AEs 425 6.19 (59%) 4.23 (44%) 31 <0.0001
 Fever 154 7.50 (68%) 4.30 (44%) 26 <0.0001
 Diarrhea 129 4.95 (49%) 4.37 (45%) 1 NS
 Respiratory 154 6.92 (64%) 4.31 (44%) 19 <0.0001
 Skin 114 5.41 (54%) 4.36 (45%) 3 0.09
*P values obtained from multilevel linear modeling included subject, treatment group, and time as covariates.   †Number of reported illnesses at twice weekly 
fieldworker visits coinciding with hepcidin measurements (total n = 5113).   ‡Number of recorded AEs coinciding with hepcidin measurements ±4 days (total 
n = 5113).
0.5
0.1
0.05
Fig. 2. Attenuation in the range of interindividual characteristic hepcidin levels 
after multivariate adjustment for iron status and inflammation. Blue dots indicate 
each child’s estimated mean hepcidin value after multivariate adjustment for ferritin, 
CRP, UIBC, and granulocyte number. In the unadjusted data, green indicates habitual 
iron absorbers (hepcidin <5.5 ng/ml); red indicates habitual iron blockers (hepcidin 
>5.5 ng/ml). The horizontal red line shows the threshold separating absorbers from 
nonabsorbers.
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reduces their risk of infection. These new insights may help explain 
why iron supplementation programs that have used unphysiological 
large bolus doses of highly absorbable iron, in an attempt to over-
come this blockade, have frequently caused iatrogenic harm (27).
The chief strengths of this study are the repeated measures of 
hepcidin and very comprehensive panels of iron and hematological 
status and of inflammation in a large sample of children in a typical 
rural African setting with a very high burden of anemia. A weakness is 
that we did not measure iron absorption directly and have separated 
iron absorbers from nonabsorbers using a previously defined thresh-
old established in children of a similar age and in the same setting.
Identifying the key drivers of the inflammation now becomes a 
research priority. If it derives from a generalized exposure of all 
mucosal surfaces to pathogens, then the fact that such mild inflam-
mation up-regulates hepcidin suggests that there will be a very high 
hygiene threshold that needs to be exceeded. However, our data also 
point to a hitherto undiscovered etiological factor in iron-refractory 
IDA, namely, respiratory infections, which may, in turn, relate to 
air pollution such as from wood fires or, in The Gambian setting, 
dust in the dry season.
Proof-of-principle studies are required to test whether anti- 
inflammatory interventions could ameliorate IDA, and administra-
tion of galacto-oligosaccharides has already shown promise (28, 29). 
The use of orally active anti-hepcidin compounds that are currently 
under development could also be informative, but using compounds 
that overrule the evolved iron-restricting function of hepcidin would 
need to be conducted under the most rigorous medical cover and 
is unlikely ever to represent realistic therapeutic options in low- 
income settings.
We conclude that, in areas with high levels of infections, attempts 
to combat ID by traditional means will continue to have low efficacy 
and high levels of side effects unless accompanied by radical improve-
ments in children’s living conditions sufficient to reduce or eliminate 
even low-grade inflammation with a special focus on ameliorating 
respiratory infections. An additional inference of relevance to global 
food policy is that children may be able to maintain adequate iron 
status even on diets containing low levels of animal products if and 
when their low-grade inflammation can be eliminated.
MATERIALS AND METHODS
Ethics
The study was approved by The Gambia Government/MRC Joint 
Ethics Committee (SCC/EC ref. no. 1358), and parents gave written 
consent following a detailed oral description and receipt of a written 
informed consent document.
Participants and setting
In the course of a randomized controlled trial to test the utility of a 
hepcidin-guided screen-and-treat approach to iron supplementa-
tion (ISRCTN 07210906) (13), we conducted a post hoc exploratory 
analysis of serial finger-prick plasma hepcidin weekly for 12 weeks 
(maximum, 13 measurements; total n = 5113) in 407 rural Gambian 
children aged 6 to 23 months at recruitment (see Table 1 for base-
line characteristics). The children were recruited in five cohorts 
between 26 May 2014 and 10 August 2015 to cover both rainy and 
dry seasons. All children were preselected as having Hb <11 g/dl at 
screening. At recruitment, 783 families consented to be screened, 
but 104 could not be called because they had traveled and a further 
56 were called but did not attend. Of the 623 who attended, 10 were 
excluded on health grounds and 64 were below the preset exclusion 
criterion of <–3 SD for weight-for-age or height-for-age. Venous 
bleeding was not achieved for four children, one family refused, and 
one child was found to be too young. Of the remaining 543 children, 
136 had Hb values >11 g/dl, leaving 407 children (75%) who were 
randomized. Randomized children received multiple micronutrient 
powders (MMPs) either with or without supplemental iron at varying 
levels: group 1, “universal iron supplementation” with 12 mg of iron 
(as ferrous fumarate) daily; group 2, weekly “screen-and-treat” iron 
supplementation using MMP with 12 mg of iron daily for a week if 
the previous hepcidin was <5.5 ng/ml (otherwise MMP without iron); 
group 3, weekly “screen-and-treat” iron supplementation using 
MMP with 6 mg of iron daily for a week if the previous hepcidin was 
<5.5 ng/ml (otherwise MMP without iron) (13). Height and weight 
were assessed using standard techniques and converted to z scores 
using WHO Anthrops (30).
Hematology and biochemistry
At 0, 49, and 84 days, we took venous blood to perform a full blood 
count (Medonic M20M GP analyzer) and analyzed plasma iron sta-
tus (serum iron, UIBC, ferritin, transferrin, sTfR, and TSAT) as well 
as markers of inflammation (CRP and AGP) (all by Roche COBAS 
INTEGRA 400 plus). Hepcidin was analyzed using the Bachem 
Human Hepcidin 25 ELISA (Peninsular Laboratories LLC, San 
Carlos, USA), which had been validated in a worldwide hepcidin 
assay harmonization exercise involving both mass spectrometric 
and immunochemical assays (31). The intra-assay coefficient of vari-
ation was 8.7%. In 11.2% of cases, where hepcidin levels exceeded 
the linear portion of the ELISA calibration plot (>50 ng/ml), we re-
peated the analysis after further sample dilution where the sample 
AA 50th centile
AA 5th centile
Fig. 3. Hb levels in rural Gambian children compared to U.S. reference data for 
African Americans. Mean Hb levels from healthy rural Gambian children partici-
pating in the Keneba Biobank compared to reference data from African Americans 
(AA) living in the United States (24). Blue, boys; pink, girls. 1 to 1.99 years, n = 344; 
2 to 2.99 years, n = 563; 3 to 3.99 years, n = 518; 4 to 4.99 years, n = 495; 5 to 5.99 years, 
n = 446; 6 to 9.99 years, n = 1877. Numbers within columns are percent anemia 
against WHO cutoff (11 g/dl). Green bars represent WHO meta-analyzed average 
benefit of iron-plus-multiple-micronutrient randomized trials (3, 4). Green numbers 
in columns are the predicted anemia rates that would remain after iron-containing 
micronutrient interventions (3, 4).
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was available, but in 7.9% of cases allocated the value of 50 ng/ml. 
The lower limit of detection was 0.098 ng/ml, and we set half of the 
detection limit as the lowest possible value (i.e., 0.049 ng/ml).
Statistical analysis
The power calculations used to determine the sample size were based 
on the objectives of the clinical trial and have been reported elsewhere 
(13). All participants were included in the current analysis. Variables 
with skewed distribution (hepcidin, ferritin, CRP, AGP, and fecal 
calprotectin) were log-transformed. Multilevel linear modeling and 
linear regression were performed using DataDesk 7.0.2 (Data 
Description Inc.). All multilevel models included subject (discrete 
variable and random intercept) and day of study (continuous) as 
independent variables. Forward selection (acceptance threshold 
at P < 0.05) was used to determine the variables for inclusion in 
multivariate analysis of factors predicting hepcidin. None of age, 
sex, length-for-age, or weight-for-age were significant predictors of 
hepcidin and hence were not included in the model. The relative 
strengths of associations between hepcidin and its putative regula-
tors were assessed by the F ratio. Children’s mean hepcidin values 
adjusted for iron status (UIBC), inflammation (CRP), or both were 
computed using the estimated cell means command in the linear 
models package of DataDesk. On the basis of previous stable isotope 
iron absorption studies in children within the same setting, we used 
a hepcidin threshold of 5.5 ng/ml to separate iron absorbers from 
nonabsorbers (12, 16). Note that the Bachem ELISA test used here 
is the same as that used to determine the absorption threshold 
(5.5 ng/ml) (16), and longitudinal stability was checked as part of 
the regular quality control. Children were scored as being infected 
(yes/no) at the twice weekly fieldworker assessments if the mothers 
reported any of fever, vomiting, diarrhea, cough, or “other illness” 
or if the child had an axillary temperature of >37.5°C. Nurse- 
ascribed AEs were listed as all events or subclassified as fever, diar-
rhea, respiratory or skin infections, where such events could coexist 
and were counted separately (e.g., a child with fever and respiratory 
infection would contribute to each analysis). Malaria contributed 
only three AEs and hence could not be analyzed.
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